PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.16
D/E ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.03. Howard Marks would check for debt covenant compliance and refinancing risks.
-0.01
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 10.62. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
324.53
Positive coverage while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch would investigate our competitive advantages in a distressed sector.
2.46
Current ratio 50-75% of Drug Manufacturers - Specialty & Generic median of 3.67. Martin Whitman would look for hidden assets or working capital optimization.
37.30%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.13%. Michael Burry would check for aggressive accounting and hidden risks.